1)Moore K, et al : Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379 : 2495-2505, 2018
2)Konstantinopoulos PA, et al : Homologous recombination deficiency : exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 5 : 1137-1154, 2015
3)中央社会保険医療協議会総会(第471回)資料【総-1-1】医療機器及び臨床検査の保険適用について.https://www.mhlw.go.jp/content/12404000/000708962.pdf
4)Ray-Coquard I, et al : Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381 : 2416-2428, 2019
5)González-Martín A, et al : Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381 : 2391-2402, 2019
6)Moore KN, et al : Niraparib monotherapy for late-line treatment of ovarian cancer(QUADRA) : a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20 : 636-648, 2019
7)Akagi K, et al : The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci, 2021(Online ahead of print)
8)Latham A, et al : Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37 : 286-295, 2019
9)FoundationOne® CDxがんゲノムプロファイル添付文書2021年6月改訂(第13版).https://www.chugai-pharm.co.jp/news/detail/20210622170000_1115.html